Objectives. The Medical Outcome Survey short-form 36 (SF-36) is widely used in studies of PsA. We test the fundamental scaling assumptions for the validity of SF-36 eight scales and two summary scores in PsA.
Introduction
PsA is recognized as a unique entity with chronic inflammatory changes over joint or enthesis in association with psoriasis. Specific clinical features that distinguish PsA from other arthropathies include nail dystrophies, distal phalangeal joint (DIPJ) involvement, dactylitis, enthesitis, osteolysis, periaricular new bone formation, asymmetrical sacroiliitis and spondylitis. PsA has a wide range of clinical manifestations and subsets have been described since the 1970s. Five patterns of disease subsets were described by Moll and Wright [1] , including DIPJ-only, asymmetrical oligoarthritis, symmetrical polyarthritis, spondylitis and arthritis mutilans. Considerable overlaps between subsets have been recognized, and asymmetrical oligoarthritis and symmetrical polyarthritis were noted to change with time and with treatment [2] [3] [4] . Some authors advocated classification into two broad subsets: peripheral disease and axial disease [5, 6] . The Classification of Psoriatic Arthritis (CASPAR) criteria were recently developed as agreed and validated criteria for the classification of PsA [7] . The criteria were derived from a prospective, multi-centre observational study of 588 consecutive clinical patients with PsA and 536 controls with other inflammatory arthritis. It gives a sensitivity and specificity of 0.914 and 0.987 to classify PsA from non-PsA. It has been validated in the Chinese population [8] and in early PsA cohorts [9, 10] .
There has been widespread use of patient-reported rating scales in measurement in the field of rheumatology. Health rating scales can be disease specific or generic. A major advantage of using generic scales is that they enable comparison across different diseases. The use of generic rating scales requires that they satisfy minimum psychometric assumptions [11, 12] . These assumptions are frequently untested and affect the quality of measurement in clinical trials.
Quality of life (QoL) is an important and core evaluation in many chronic arthritides including PsA. Although a disease-specific quality of life assessment instrument for PsA has been developed [13] , it is still undergoing validation. The Medical Outcome Health Survey (MOS) short-form 36 (SF-36) is a generic measure of QoL [14] . It has been widely used in different disease entities including randomized therapeutic trials in PsA [15] [16] [17] . It allows comparison across different diseases. The SF-36 has eight scales generated by summing up items, including physical functioning (PF), role limitation due to physical problem (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitation due to emotional problem (RE) and mental health (MH). These eight scales provide a comprehensive assessment of QoL. There are two summary scores [physical component summary (PCS) and mental component summary (MCS) scores] that are generated by combining weighted subscale scores. The summary scores have better measurement precision, smaller confidence intervals, less floor or ceiling effects [10, 18] and most of all, are simple to use and interpret in clinical trials. The summary scores can also be transformed to a norm base of the general population with a mean of 50 and S.D. of 10. The Chinese (Hong Kong) version of SF-36 and the summary scores have been validated [19, 20] , and the Hong Kong norm has been established on 2410 subjects [21] .
The International Quality of Life Assessment (IQOLA) project has developed a three-stage method for crosscultural adaptation of the MOS SF-36 [22] . The first is translation of the original SF-36 into native language to ensure equivalence. The second stage is formal psychometric tests of the assumptions underlying item scoring and construction of multi-item scales, to make sure that the algorithms can be applied to the population concerned. The third stage is the validation and norming studies.
Only a few studies have examined the psychometric properties of SF-36 in PsA [23, 24] . The PF scale has been evaluated by item response theory [23, 24] . However, no study has examined the fundamental test for scaling assumptions of SF-36 in PsA. The tests of scaling assumptions determine whether it is legitimate to generate the eight scales and the two summary scores. Psychometric properties are sample dependent. The performance of a measure in a specific disease entity could be different from its performance in the general population and the former aspect is usually more important. The purpose of this article was to test the scaling assumptions, reliability and validity in PsA according to the methods outlined by the IQOLA project, and to confirm that it is appropriate to use in PsA [25] .
Methods

Data collection
All patients with PsA according to the CASPAR criteria [7] and who attended an outpatient specialist clinic in a single centre from January 2008 to December 2008 were recruited. The study was reviewed and approved by the Joint Chinese University of Hong Kong-New Territories East cluster clinical research ethics committees. Before entering, participants were informed of the nature and purpose of study. Every patient signed an informed consent form before entering the study. All patients were Han Chinese and read traditional Chinese characters. These patients were assessed according to a standard protocol. Demographic and disease characteristic data collected include joint counts, skin activity, pain scores, global health assessment and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Functional status by HAQ and QoL by SF-36 Chinese (Hong Kong) version were collected.
Test of scaling assumptions
The SF-36 scale scores were constructed using summated rating or Likert scale construction. Five basic assumptions must be satisfied [10, 22, 25] .
(i) Equal item variance. Items measuring the same concept should have approximately equal variances (S.D.) [22, 25] . Otherwise, their respective contribution to the total score variability would be unequal, and the computation of the total score would require standardization of items before summation. We report S.D. ranges for all scales. (ii) Item internal consistency. An item should be quite linearly related to the underlying concept being measured. The item-scale correlation corrected for overlap for coefficients should be >0.4 [25] . (iii) Equality of item-scale correlations. Items in a given scale should contain approximately the same proportion of information about a concept and therefore the item-scale correlation within a scale should be roughly equal. (iv) Item discriminant validity. An item should correlate better with its hypothesized scale than with scales measuring other concepts. The statistical significance of the difference between the item-own and item-other scale correlation was tested by Steiger's t-test [26] . Definite scaling success is met if the difference between the item-own and itemother scale correlation were >2 S.D. (>0.15).
(v) Reliability and interpretable scale score. The internal reliability of scale scores was measured by Cronbach's a-coefficient (Cronbach's a). A minimal reliability coefficient should be >0.7 for group comparison [27] . If each scale measures a unique concept, the correlation between scales should be less than their internal reliability coefficient.
Construct validity
Construct validity was assessed by convergent and divergent validity; and checking the known group validity. Substantial correlation (Pearson's r > 0.40) was hypothesized between scales that were conceptually related (convergent validity). For the evaluation of how distinct each scale was from other scales (divergent validity), inter-scale correlations were compared with internal consistency reliability coefficients (Cronbach's a). Known group validity was tested by comparing scale scores across groups known to be different [28] . Patients were grouped under severe disease based on HAQ > 1.0, BASDAI > 50 and DAS28 > 5.1. The ability of instruments to differentiate between known groups was calculated as the statistically significant differences between groups. The effect size was calculated as the standardized mean difference described by Cohen [29] . The difference in mean scores was divided by the pooled S.D. The effect size was categorized as small (0.2-0.5), medium (0.5-0.8) or large (>0.8).
Validity of summary scores
The summary scores PCS and MCS were generated according to the manual [13, 19] and with the Hong Kong population data [21] . Two scaling assumptions should be satisfied for the reporting of SF-36 PCS and MCS. 
Results
A total of 168 subjects (90 males, 78 females) were studied. The mean (S.D.) age and illness duration were 47.7 (11.9) and 8.4 (7.3), respectively. All patients were Han Chinese descendents. The demographic and disease characteristics are summarized in Table 1 . Ten (6%) patients and 128 (76.7%) subjects had pure spinal disease and peripheral joint disease, whereas 17.3% had mixed spinal and peripheral joint disease. Enthesitis and dactylitis were noted in 42.2 and 55.1% of our subjects during assessment. Dactylitis was reported in 3.7-53% in PsA cohorts [2-4, 30, 31] . More recent studies showed higher prevalence that may reflect an increased awareness of this manifestation in PsA. We reported a somewhat high prevalence of dactylitis in Chinese. This may be related to a selection bias towards a group of patients with greater severity as our patients were from a tertiary referral centre.
Other reasons include an increased awareness of dactylitis among rheumatologists and ethnicity factors. The PsA cohort has poor QoL as compared with the Hong Kong general population in all eight SF-36 scales ( Table 2 ). The norm-based mean (S.D.) PCS and MCS scores of the PsA cohort were 31.6 (14.2) and 45.2 (12.7), respectively, which were well below those of the normal population [mean 50 (S.D. 10)]. Table 3 lists the mean scores and S.D.s of the eight scales of SF-36. The distributions of scores showed good spread. A mild ceiling effect was noted with SF. RP and RE exhibited substantial ceiling and floor effect due to its dichotomous response format.
Tests of scaling assumptions
The S.D.s of all scales and the Pearson's item-scale correlation between each item and scale were shown in supplementary Appendix 1 available as supplementary data at Rheumatology Online. The items within each scale had similar S.D.s, satisfying scaling assumption of equal item variances (Assumption i). The correlations between each item with its hypothesized scale corrected for overlaps were all 50.4 (scaling Assumption ii on internal consistency). The item-own correlations within the same scale were generally similar (Assumption iii). The item-own scale correlations were generally higher than the itemother scale correlations (Assumption iv). The scaling success rate on discriminant validity was 100% for all scales, except the GH scale. Most item-own scale correlations exceeded item-other correlations by at least 2 S.E.s (>0.15) indicating definite scaling success. The scaling success rate for GH was only 90% as GH1 had a lower www.rheumatology.oxfordjournals.org correlation with its hypothesized scale than with four of the eight competing scales. In GH2 and GH3, a notable proportion of item-own scale correlations exceeded itemother scale correlations by <2 S.E. (<0.15). This indicated that items in these two scales were limited in their ability to discriminate between constructs that are hypothesized to be different. Cronbach's a-coefficients of internal reliability (Cronbach's a), ranged from 0.749 to 0.913 and were all above the standard of 0.7. The inter-scale correlations were less than the scale internal reliability coefficient showing that each scale measured a unique concept relative to others (Assumption v of reliability and interpretable scale score).
Construct validity
Higher inter-scale coefficients were found between scales that represent similar constructs (e.g. VT and MH) than those with competing constructs (e.g. PF and RE) as shown in Table 4 . Most of the inter-scale correlation coefficients were low to medium (0.33 to 0.70), meaning that the scales constructs were generally distinct.
Known group validity was tested by comparing scale scores across groups known to be different. Patients were grouped under severe disease based on HAQ >1.0, BASDAI > 50 and DAS-28 > 5.1. All eight SF scales and summary scores in the severe groups were significantly worse than the less severe groups (data not shown). It means that SF-36 scales and summary scores were able to show difference between severe and nonsevere groups. Medium effect size was observed in the majority of scales. Validity of summary scores PCA of inter-correlations among SF-36 scales extracted two components. Table 5 shows the hypothesized association and the rotated factor loadings between the eight scales and the two summary components (physical/ mental). These two components explained 69.4% of the total variance and 73.7-99.9% of the total reliable variance in all SF-36 scales. This supported the 2D model of health underpinning the SF-36 in PsA.
Discussion
Our study has comprehensively evaluated the basic scaling assumptions underpinning the scoring of SF-36 in patients with PsA. Scaling assumptions were basically satisfied for the eight scales and the two summary scores.
A minor scaling problem was noted with GH, scaling success rate was 90%. The item-own correlation of GH1 was lower than four item-other correlations. This may mean that GH1 in this cohort could be affected or confounded by other concepts like physical disability. However, this minor discrepancy was not considered a significant problem when all items contribute fully to the total score [25] . The high internal consistency reliability by the Cronbach's coefficient (Cronbach's a) and low inter-scale correlations supported that each of the eight scales measured a unique concept. The current study also supports that the PCS and MCS provide a valid [32] . The limitation of these dichotomous items could be minimized by expanding the Likert response in Version 2 of the SF-36.
Our study revealed the high impact on QoL in patients with PsA as compared with the general population. These patients had high functional disability. The mean PF score was much lower than that of normal population. The ceiling effect of PF was only 7.7%, which was also lower than that in other population samples which were usually >20% [32] . Both the PCS and MCS were significantly lower than that of the general population.
Although a disease-specific QoL assessment instrument for PsA has been developed [13] , it is still under validation. There is no validated Chinese translation for this instrument. The eight scales of SF-36 and the summary scores have been validated in different populations and languages, including a Chinese (Hong Kong) version. SF-36 has also been the most widely used QoL instrument in epidemiology studies and controlled trials in PsA. A key advantage of generic scales over disease-specific scales is that comparison across disease is possible. It is important that the spectrum of health covered by an instrument matches that of the study sample. Our current study therefore provides comprehensive assessment in the fundamental criteria of scaling assumption and construct validity, which supports the use SF-36 in PsA. The results also supported the reporting of the PCS and MCS to provide a valid summary of the eight scales.
Our study has several limitations. All of our patients were Han Chinese descendents and we have been using the Hong Kong general population as comparison. The application to other ethnicity, language of SF-36 cross-culturally may need further evaluation. Besides, the PsA cohort is from a tertiary referral centre and data may not be generalized to the general population of PsA. Bold values indicate Cronbach's a-coefficients of internal reliability (Cronbach's a), which are higher than the cut-off of 0.7 and are higher than the inter-scale correlations.
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Moreover, it is a cross-sectional study and could not provide information on the responsiveness to change of the instrument with time and treatment.
Conclusion
We demonstrated that psychometric properties of the SF-36 in PsA were satisfactory according to the criteria set by the IQOLA project protocol. The use of summated rating methods of the SF-36 and the reporting of the two summary scores in PsA was supported.
Rheumatology key messages
. SF-36 has been widely used in studies in PsA, but the fundamental assumption for its validity has not been tested. . We provide validation data for use of the SF-36 eight scales and summary scores in PsA.
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